Literature DB >> 25814087

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.

Markus Pfirrmann1, Michael Lauseker, Verena S Hoffmann, Joerg Hasford.   

Abstract

Nowadays in many fields of medicine, prognostic scores are used to predict the outcome for individual patients. In chronic myeloid leukemia (CML), the Sokal, the Euro, and the EUTOS score are established prognostic scores which were addressed by the CML management recommendations of the European LeukemiaNet. This review provides a general definition of prognostic scores and explains their meaning. Main differences between the Sokal, the Euro, and the EUTOS score are highlighted. Due to the therapeutic success of tyrosine kinase inhibitors, the proportion of patients with causes of death unrelated to CML is growing. To assess the potential of a drug to prevent dying of CML, causes of death unrelated to CML need to be considered as competing risks. Supported by data of patients randomized to imatinib-based treatments within the German CML study IV, this review also explores the prognostic performance of the established scores if the primary event is death due to CML only and explains the implicit statistical particularities when treating other causes of death as competing risks. In the presence of competing risks, the application of both the cause-specific hazard model and the subdistribution hazard model is recommended when investigating the influence of prognostic factors on the event of interest. Another purpose of this work is to foster the ability of hematologists to interpret the outcome of a cause-specific hazard and a subdistribution hazard model and to understand the differences between them.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25814087     DOI: 10.1007/s00277-015-2316-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

2.  Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Z Chen; J E Cortes; J L Jorgensen; W Wang; C C Yin; M J You; E Jabbour; H M Kantarjian; L J Medeiros; S Hu
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

3.  PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

Authors:  Juan M Alonso-Dominguez; Luis Felipe Casado; Eduardo Anguita; Maria Teresa Gomez-Casares; Ismael Buño; Francisca Ferrer-Marín; Alicia Arenas; Rafael Del Orbe; Rosa Ayala; Pilar Llamas; Rocio N Salgado; Santiago Osorio; Pedro Sanchez-Godoy; Carmen Burgaleta; Ignacio Mahíllo-Fernández; Valentin Garcia-Gutierrez; Juan Luis Steegmann; Joaquín Martinez-Lopez
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

4.  MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.

Authors:  Qiang Guo; Junwen Luan; Ni Li; Zhen Zhang; Xiaoxiao Zhu; Lin Zhao; Ran Wei; Linlin Sun; Yin Shi; Xunqiang Yin; Na Ding; Guosheng Jiang; Xia Li
Journal:  Oncotarget       Date:  2017-07-12

5.  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Authors:  R Hehlmann; M Lauseker; S Saußele; M Pfirrmann; S Krause; H J Kolb; A Neubauer; D K Hossfeld; C Nerl; A Gratwohl; G M Baerlocher; D Heim; T H Brümmendorf; A Fabarius; C Haferlach; B Schlegelberger; M C Müller; S Jeromin; U Proetel; K Kohlbrenner; A Voskanyan; S Rinaldetti; W Seifarth; B Spieß; L Balleisen; M C Goebeler; M Hänel; A Ho; J Dengler; C Falge; L Kanz; S Kremers; A Burchert; M Kneba; F Stegelmann; C A Köhne; H W Lindemann; C F Waller; M Pfreundschuh; K Spiekermann; W E Berdel; L Müller; M Edinger; J Mayer; D W Beelen; M Bentz; H Link; B Hertenstein; R Fuchs; M Wernli; F Schlegel; R Schlag; M de Wit; L Trümper; H Hebart; M Hahn; J Thomalla; C Scheid; P Schafhausen; W Verbeek; M J Eckart; W Gassmann; A Pezzutto; M Schenk; P Brossart; T Geer; S Bildat; E Schäfer; A Hochhaus; J Hasford
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

Review 6.  Prospects for achieving treatment-free remission in chronic myeloid leukaemia.

Authors:  Giuseppe Saglio; Robert P Gale
Journal:  Br J Haematol       Date:  2020-02-14       Impact factor: 6.998

7.  Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.

Authors:  Yi-Jiun Su; Ming-Chung Kuo; Tsai-Yun Chen; Ming-Chung Wang; Youngsen Yang; Ming-Chun Ma; Tung-Liang Lin; Tung-Huei Lin; Hung Chang; Chieh-Lin Jerry Teng; Pei-Ching Hsiao; Chih-Cheng Chen; Po-Nan Wang; Lee-Yung Shih
Journal:  Cancer Sci       Date:  2022-08-17       Impact factor: 6.518

Review 8.  The underestimated role of basophils in Ph+ chronic myeloid leukaemia.

Authors:  Peter Valent; Hans-Peter Horny; Michel Arock
Journal:  Eur J Clin Invest       Date:  2018-08-06       Impact factor: 4.686

9.  Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016.

Authors:  Jimena Ylescas-Soria; Alfredo H de la Torre-Lujan; Luis A Herrera; Daniela Miranda; Flavio Grimaldo; Silvia Rivas; Eduardo Cervera; Abelardo Meneses-García; Fidias E Leon-Sarmiento; Diddier Prada
Journal:  Cancer Med       Date:  2019-05-02       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.